Table 2 The results of analytic performance within dual-MAbs CLIA kit and the proposed assay.
From: Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3
dual-MAbs CLIA kit | Proposed assay | ||
|---|---|---|---|
Detect limitation | 0.05 ng/mL | 0.03 ng/mL | |
Linearity | 0.9999 | 0.99999 | |
Linear range | 0–500 ng/mL | 0.03–600 ng/mL | |
Specificity | 0.015–0.021% | 0–0.002% | |
Accuracy | 94.50–106.80% | 91.80–104.53% | |
Precision | Intra-assay | 4.76–5.42% | 6.06–7.60% |
Inter-assay | 6.41% | 7.14–8.98% | |
Stability (2–8 °C) | sealed | 12 months | 12 months |
uncovered | 30 days | 14 days | |
